MPV as a Predictor for ACS in Patients With MASLD
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients aged ≥18 years.
Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria).
Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I.
MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II.
Disqualifiers
Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease).
Patients with known hematological disorders affecting platelet count or function.
Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling.
Patients with active infection, inflammatory diseases, or malignancy.
Trial population
The study population will consist of adult patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) who are admitted to or evaluated at Sohag University Hospital. Eligible participants will include patients with confirmed MASLD based on clinical evaluation, laboratory findings, and imaging studies. The study will include two groups: patients with MASLD who present with acute coronary syndrome (ACS) and patients with MASLD without evidence of ACS. Participants will be recruited from inpatient and outpatient services, including the cardiology and internal medicine departments. Demographic and clinical data, cardiovascular risk factors, and laboratory parameters-including mean platelet volume (MPV)-will be collected at baseline
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsGroup A: Group I: MASLD patients with acute coronary syndrome (ACS).
Group B: Group II: MASLD patients without acute coronary syndrome
Trial outcomes
Primary outcomes
1
Mean platelet volume as a predictor for acute coronary syndrome in patients with metabolic dysfunction-associated steatotic liver disease
To evaluate the association between mean platelet volume (MPV) levels and the presence of acute coronary syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Time frame
At hospital admission / baseline assessment.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: